RussellWJenkinsMDPhD

Oncology • Boston, MA

Hematologic Oncology, Melanoma

Instructor

Join to view full profile

Dr. Jenkins is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jenkins' full profile

Already have an account?

Office
MGH Cancer Center
55 Street, Jackson 904B
Boston, MA 02114
Phone+1 617-726-9372

Fax+1 844-542-5959

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2014 - 2018
Massachusetts General HospitalResidency, Internal Medicine, 2013 - 2014
Massachusetts General HospitalInternship, Internal Medicine, 2012 - 2013
Medical University of South CarolinaClass of 2012

Certifications & Licensure

MA State Medical License 2015 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Use of patient-derived organotypic tumor spheroids for testing of viral vector gene therapy in combination with checkpoint blockade.
Ana Carolina M Domingues, Soraia B de Oliveira, Nayara G Tessarollo, Ana Paula Lepique, Otavio Rodrigues
Molecular Therapy. Oncology. 2025-03-20
TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids.
Yi Sun, Luke Maggs, Apekshya Panda, Samuel J Wright, Angelina M Cicerchia
Cancer Immunology Research. 2025-02-03
Real-world data confirms limited efficacy of dual programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 immune checkpoint blockade in acral l...
David X Zheng, Russell W Jenkins
The British Journal of Dermatology. 2025-01-24

Journal Articles

Tumor Innate Immunity Primed by Specific Interferon-Stimulated Endogenous Retroviruses
Scott Rodig, Ewa Sicinska, Thanh Uyen Barbie, David Allen Barbie, Russell William Jenkins, Ravindra Uppaluri, Rohit Thummalapalli, Jacob Sands, Nature

Press Mentions

Study Identifies TBK1 as Key to Overcoming CAR T ResistanceJanuary 9th, 2025
Melanoma Research Alliance Announces $8.2 Million for 33 Grant Awards to Advance Melanoma ResearchApril 30th, 2019

Grant Support

Dissecting the tumor-intrinsic and -extrinsic roles of TBK1 in tumor immunityMASSACHUSETTS GENERAL HOSPITAL2023–2028